NYSEMKT: AIMAim Immunotech Revenue
Aim Immunotech revenue was $112.00k for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $26.0k, up 4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AIM annual revenue was $170.0k, with -15.8% growth year-over-year.
AIM past revenue growth
How has AIM's revenue growth performed historically?
Company
-41.05%
Industry
284.61%
Market
22.91%
AIM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AIM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AIM's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
AIM revenue history
Current Revenue
$112.0k
Current Earnings
-$15.8M
Current Profit Margin
-14,062.5%
Be the first to know when AIM announces revenue.
AIM Revenue History By Year
| AIM Yearly Revenue | AIM Revenue | AIM Change | AIM Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $170.00k | -$32.00k | -15.84% |
| 2023-12-31 | $202.00k | $61.00k | +43.26% |
| 2022-12-31 | $141.00k | $6.00k | +4.44% |
| 2021-12-31 | $135.00k | -$28.00k | -17.18% |
| 2020-12-31 | $163.00k | $23.00k | +16.43% |
| 2019-12-31 | $140.00k | -$227.00k | -61.85% |
| 2018-12-31 | $367.00k | -$70.00k | -16.02% |
| 2017-12-31 | $437.00k | $345.00k | +375.00% |
| 2016-12-31 | $92.00k | -$41.00k | -30.83% |
| 2015-12-31 | $133.00k | -$64.00k | -32.49% |
| 2014-12-31 | $197.00k | $47.00k | +31.33% |
| 2013-12-31 | $150.00k | -$63.00k | -29.58% |
| 2012-12-31 | $213.00k | $52.00k | +32.30% |
| 2011-12-31 | $161.00k | $26.00k | +19.26% |
| 2010-12-31 | $135.00k | $24.00k | +21.62% |
| 2009-12-31 | $111.00k | -$154.00k | -58.11% |
| 2008-12-31 | $265.00k | -$794.00k | -74.98% |
| 2007-12-31 | $1.06M | $126.00k | +13.50% |
| 2006-12-31 | $933.00k | -$150.00k | -13.85% |
| 2005-12-31 | $1.08M | -$146.00k | -11.88% |
| 2004-12-31 | $1.23M | $572.00k | +87.06% |
| 2003-12-31 | $657.00k | -$247.00k | -27.32% |
| 2002-12-31 | $904.00k | $514.00k | +131.79% |
| 2001-12-31 | $390.00k | -$398.00k | -50.51% |
| 2000-12-31 | $788.00k | $110.00k | +16.22% |
| 1999-12-31 | $678.00k | $277.00k | +69.08% |
| 1998-12-31 | $401.00k | $142.29k | +55.00% |
| 1997-12-31 | $258.72k | $226.67k | +707.37% |
| 1996-12-31 | $32.04k | -$2.93M | -98.92% |
| 1995-12-31 | $2.97M | $2.79M | +1,587.50% |
| 1994-12-31 | $175.76k | N/A | N/A |
Aim Immunotech Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.